Beijing University of Chinese Medicine | China
Dr. Jingfang Zhang, Associate Professor at the School of Life Sciences, Beijing University of Chinese Medicine, is a distinguished researcher in molecular biology, cancer biology, and genome editing. Her work focuses on understanding cellular behavior and disease mechanisms through advanced genetic and pharmacological tools. With expertise in cancer biology and stem cell research, she integrates stem cell biology, pharmacology, and gene regulation. Dr. Zhang has pioneered drug-inducible and multimode CRISPR/Cas systems, including the HIT-Cas9 platform, enabling precise control of gene expression and genome editing. Her groundbreaking innovations have expanded the versatility and safety of genome-editing technologies for therapeutic applications. Her research, published in Nucleic Acids Research, Blood, and Molecular Therapy – Nucleic Acids, advances epigenetics and therapeutic applications. She has also provided key insights into hematologic malignancies and acute myeloid leukemia. Supported by the National Natural Science Foundation of China, she fosters interdisciplinary research and mentors young scientists. Dr. Zhang’s projects bridge molecular biology and translational medicine, opening new avenues for targeted therapies. Her innovations in genome editing and cellular reprogramming are shaping precision medicine, regenerative therapeutics, and the future of molecular life sciences.
Publications
Wang, Y., Hu, J., & Zhang, J. (2025). Evaluation of abnormal growth-related genes of hematopoietic stem and progenitor cells by combining CRISPR/Cas9 technology with cell counting. Journal of Visualized Experiments: JoVE, (219).
Zhang, J., Chen, L., Zhang, J., & Wang, Y. (2019). Drug inducible CRISPR/Cas systems. Computational and Structural Biotechnology Journal, 17, 1171–1177.
Zhao, C., Zhao, Y., Zhang, J., Lu, J., Chen, L., Zhang, Y., Ying, Y., Xu, J., Wei, S., & Wang, Y. (2018). HIT-Cas9: A CRISPR/Cas9 genome-editing device under tight and effective drug control. Molecular Therapy – Nucleic Acids, 13, 208–219.
Lu, J., Zhao, C., Zhao, Y., Zhang, J., Zhang, Y., Chen, L., Han, Q., Ying, Y., Peng, S., Ai, R., et al. (2018). Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. Nucleic Acids Research, 46(5), e25.
Zhang, J., Kong, G., Rajagopalan, A., Lu, L., Song, J., Hussaini, M., Zhang, X., Ranheim, E. A., Liu, Y., Wang, J., et al. (2016). p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. Blood, 129(3), 358–370.